Effects of the ACE inhibitor, enalapril, in children age 6–16 years with hypertension

Soffer, Beth A.; Shahinfar, Shahnaz; Shaw, Wayne; Zhang, Z; Herrera, Pamela; Frame, V.; Wells, Thomas G.

doi:10.1016/s0895-7061(00)00575-6

Cited by 10 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An enalapril suspension preparation with documented stability and known bioavailability is now available and has been used in clinical studies in children and infants with hypertension [15][16][17]. This enalapril suspension provides for greater ease and individualization of dosing in pediatric patients.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic assessment of an oral enalapril suspension for use in children

Rippley¹,

Connor²,

Boyle³

et al. 2000

Biopharm & Drug Disp

View full text Add to dashboard Cite

The angiotensin-converting enzyme (ACE) inhibitor enalapril is commonly used to treat pediatric hypertension. Because some children are unable to swallow tablets or require doses less than the lowest available enalapril tablet, an enalapril suspension was developed. This study examined the relative bioavailability of enalapril suspension (10 mg) (S) compared with 10-mg marketed VASOTEC tablets (T) in 16 healthy adult subjects. The geometric mean ratio (S/T) estimate of urinary recovery of free enalaprilat, the active moiety, was 0.92 (90% confidence interval (CI): 0.80, 1.07). Urinary recovery data indicate that approximately 50% of the dose was absorbed (50% recovered in urine as enalapril plus enalaprilat) with about 30% of the dose recovered as free enalaprilat for both S and T. The geometric mean ratios (S/T) of serum AUC and C(max) were 1.01 (90% CI: 0.90, 1.13) and 0.98 (90% CI: 0.83, 1.16), respectively. Suspension T(max) was slightly shorter (0.5 h) than that for tablet, but this difference is not clinically significant. Both formulations were well tolerated and there were no clinically significant adverse experiences. We conclude that the bioavailability of enalapril oral suspension 10-mg is similar to that of VASOTEC 10-mg tablet. Instructions for compounding enalapril are provided.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic assessment of an oral enalapril suspension for use in children

Rippley¹,

Connor²,

Boyle³

et al. 2000

Biopharm & Drug Disp

View full text Add to dashboard Cite

show abstract

“…Two pediatric enalapril studies were conducted, one a safety and efficacy trial, and the other a pharmacokinetic trial. The safety and efficacy trial enrolled 110 children aged 6 to 16 years with diastolic hypertension and demonstrated that enalapril lowered blood pressure in a dose-dependent manner with a low incidence of adverse effects [33]. The pharmacokinetic trial demonstrated similar pharmacokinetics of enalapril in infants and children compared with adults [34].…”

Section: Drug Therapy Of Childhood Hypertensionmentioning

confidence: 99%

What’s new in pediatric hypertension?

Flynn

2001

Current Science Inc

View full text Add to dashboard Cite

Research activities in the field of pediatric hypertension have been increasing in recent years, leading to important new findings in the epidemiology, diagnosis, and treatment of hypertension in children. This review summarizes recent work in these areas, focusing on the epidemic of obesity-related hypertension in children, advances in the drug therapy of childhood hypertension, and the increasing use of ambulatory blood pressure monitoring in evaluation of hypertensive children. Each of these three areas will no doubt develop further over the years ahead, resulting in further advances in the field of childhood hypertension.

show abstract

“…The experience with ACE inhibitors in children with hypertension, particularly enalapril and captopril, suggest that these agents are well-tolerated by children [38][39][40]. The most common adverse effects noted in uncontrolled studies or case series of children receiving ACE inhibitors for hypertension or other renal diseases include cough [39,[41][42][43], hypotension [44][45][46] and deterioration of renal function [46][47][48][49][50] (Table 1).…”

Section: Angiotensin-converting Enzyme Inhibitorsmentioning

confidence: 99%

“…The most common adverse effects noted in uncontrolled studies or case series of children receiving ACE inhibitors for hypertension or other renal diseases include cough [39,[41][42][43], hypotension [44][45][46] and deterioration of renal function [46][47][48][49][50] (Table 1). The decline in renal function is noted more frequently in children with preexisting renal disease [47] and is uncommon in the wellhydrated child with normal renal function [38]. Angioedema [51], hyperkalaemia [50], rash [40,47], leukopenia [40,41,47,52] and anaemia [47,53] have been reported in children receiving ACE inhibitors.…”

Section: Angiotensin-converting Enzyme Inhibitorsmentioning

confidence: 99%

Safety of the newer antihypertensive agents in children

Blowey¹

2002

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Hypertension is relatively uncommon in children and few children receive antihypertensive medications. This article reviews the safety of calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in children with hypertension. While the newer antihypertensive agents appear to be well-tolerated by children, further studies are needed to determine the safety profile across the developmental continuum, with chronic dosing and in children with complex hypertension.

show abstract

Effects of the ACE inhibitor, enalapril, in children age 6–16 years with hypertension

Cited by 10 publications

References 0 publications

Pharmacokinetic assessment of an oral enalapril suspension for use in children

Pharmacokinetic assessment of an oral enalapril suspension for use in children

What’s new in pediatric hypertension?

Safety of the newer antihypertensive agents in children

Contact Info

Product

Resources

About